Print Page  Close Window
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle  
03/18/19Paratek Pharmaceuticals Announces Management Change 
03/01/19Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
03/01/19Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference 
02/27/19Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results 
02/14/19Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference 
02/13/19Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019 
02/06/19New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections 
02/05/19Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States 
02/01/19Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
01/02/19Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)